Literature DB >> 33568453

Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase.

Ericka Kirkpatrick Roubidoux1,2, Meagan McMahon1, Juan Manuel Carreño1, Christina Capuano1, Kaijun Jiang1, Viviana Simon1,3,4, Harm van Bakel5,6, Patrick Wilson7, Florian Krammer8.   

Abstract

The influenza virus neuraminidase (NA) is becoming a focus for novel vaccine designs. However, the epitopes of human anti-NA antibodies have been poorly defined. Using a panel of 10 anti-N2 monoclonal antibodies (MAbs) that bind the H3N2 virus A/Switzerland/9715293/2013, we generated five escape mutant viruses. These viruses contained mutations K199E/T, E258K, A272D, and S331N. We found that mutations at K199 and E258 had the largest impact on MAb binding, NA inhibition and neutralization activity. In addition, a natural isolate from the 2017-2018 season was found to contain the E258K mutation and was resistant to numerous antibodies tested. The mutation S331N, was identified in virus passaged in the presence of antibody; however, it had little impact on MAb activity and greatly decreased viral fitness. This information aids in identifying novel human MAb epitopes on the N2 and helps with the detection of antigenically drifted NAs.IMPORTANCE The influenza virus neuraminidase is an emerging target for universal influenza virus vaccines. However, in contrast to influenza virus hemagglutinin, we know little about antibody epitopes and antigenic sites on the neuraminidase. Characterizing and defining these sites is aiding vaccine development and helping to understand antigenic drift of NA.
Copyright © 2021 Kirkpatrick Roubidoux et al.

Entities:  

Keywords:  N2; epitopes; influenza; mAb; neuraminidase

Year:  2021        PMID: 33568453     DOI: 10.1128/mSphere.00958-20

Source DB:  PubMed          Journal:  mSphere        ISSN: 2379-5042            Impact factor:   4.389


  5 in total

1.  Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model.

Authors:  Jessica Tan; George O'Dell; Matthew M Hernandez; Emilia Mia Sordillo; Zenab Kahn; Divya Kriti; Harm van Bakel; Ali H Ellebedy; Patrick C Wilson; Viviana Simon; Florian Krammer; Meagan McMahon
Journal:  J Virol       Date:  2021-10-20       Impact factor: 6.549

2.  Study of Antibodies to Influenza Neuraminidase N2.

Authors:  Yulia Desheva; Nadezhda Petkova; Tatiana Smolonogina; Svetlana Donina; Alexey Go
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-19

Review 3.  Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.

Authors:  Sarah Creytens; Mirte N Pascha; Marlies Ballegeer; Xavier Saelens; Cornelis A M de Haan
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

4.  Monoclonal antibodies targeting the influenza virus N6 neuraminidase.

Authors:  Shirin Strohmeier; Fatima Amanat; Juan Manuel Carreño; Florian Krammer
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

5.  Evolution of Swine Influenza Virus H3N2 in Vaccinated and Nonvaccinated Pigs after Previous Natural H1N1 Infection.

Authors:  Álvaro López-Valiñas; Laura Baioni; Lorena Córdoba; Ayub Darji; Chiara Chiapponi; Joaquim Segalés; Llilianne Ganges; José I Núñez
Journal:  Viruses       Date:  2022-09-10       Impact factor: 5.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.